FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
Uğur Şahin(Johannes Gutenberg University Mainz), Ö. Türeci(BioNTech (Germany)), Georgy M. Manikhas(City Clinical Oncology Center), Florian Lordick(Leipzig University), Andriy Rusyn, Ihor Vynnychenko(Sumy State University), Assen Dudov(Acibadem City Clinic), I. Bazin(Russian Cancer Research Center NN Blokhin), Igor Bondarenko(Dnipro State Medical University), Bohuslav Melichar(Palacký University Olomouc), Karl Dhaene, Kai Wiechen(University of Applied Sciences Worms), Christoph Huber(BioNTech (Germany)), Daniel Maurus(MerLion Pharma (Germany)), Ahsan M. Arozullah(Astellas Pharma (United States)), J.W. Park(Astellas Pharma (United States)), Martin Schüler(Deutschen Konsortium für Translationale Krebsforschung), S. Al-Batran(Krankenhaus Nordwest)
Cited by 355Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis